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ABSTRACT Elite and viremic HIV controllers are able to control their HIV infection
and maintain undetectable or low-level viremia in the absence of antiretroviral treat-
ment. Despite extensive studies, the immune factors responsible for such exclusive
control remain poorly deﬁned. We identiﬁed a cohort of 14 HIV controllers that suf-
fered an abrupt loss of HIV control (LoC) to investigate possible mechanisms and vi-
rological and immunological events related to the sudden loss of control. The in-
depth analysis of these subjects involved the study of cell tropism of circulating
virus, evidence for HIV superinfection, cellular immune responses to HIV, as well as
an examination of viral adaptation to host immunity by Gag sequencing. Our data
demonstrate that a poor capacity of T cells to mediate in vitro viral suppression,
even in the context of protective HLA alleles, predicts a loss of viral control. In addi-
tion, the data suggest that inefﬁcient viral control may be explained by an increase
of CD8 T-cell activation and exhaustion before LoC. Furthermore, we detected a
switch from C5- to X4-tropic viruses in 4 individuals after loss of control, suggesting
that tropism shift might also contribute to disease progression in HIV controllers.
The signiﬁcantly reduced inhibition of in vitro viral replication and increased expres-
sion of activation and exhaustion markers preceding the abrupt loss of viral control
may help identify untreated HIV controllers that are at risk of losing control and may
offer a useful tool for monitoring individuals during treatment interruption phases in
therapeutic vaccine trials.
IMPORTANCE A few individuals can control HIV infection without the need for anti-
retroviral treatment and are referred to as HIV controllers. We have studied HIV con-
trollers who suddenly lose this ability and present with high in vivo viral replication
and decays in their CD4 T-cell counts to identify potential immune and virological
factors that were responsible for initial virus control. We identify in vitro-determined
reductions in the ability of CD8 T cells to suppress viral control and the presence of
PD-1-expressing CD8 T cells with a naive immune phenotype as potential predic-
tors of in vivo loss of virus control. The ﬁndings could be important for the clinical
management of HIV controller individuals, and it may offer an important tool to an-
ticipate viral rebound in individuals in clinical studies that include combination anti-
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retroviral therapy (cART) treatment interruptions and which, if not treated quickly,
could pose a signiﬁcant risk to the trial participants.
KEYWORDS HIV-1 control, HIV-1 progression, cell tropism, host genetics, in vitro
virus inhibition, loss of control
There is a small proportion of HIV-1-infected individuals that spontaneously controlHIV infection (1, 2). Due to the heterogeneity among individuals with this clinical
course (3, 4) they are referred to as long-term nonprogressors (LTNP), HIV controllers,
or, in the case of undetectable viremia, elite controllers. Several factors have been
postulated to play a role in this viral control, including host genetic, immunological,
and viral factors. In particular, host genetic markers have been associated with disease
progression, yet their mechanistic action remains uncertain (5). Possibly, the strongest
predictors of HIV control include polymorphisms in HLA class I alleles, which alone or
in combination with killer cell immunoglobulin-like receptors (KIR) have been linked to
sustained low-level viremia in the absence of combination antiretroviral therapy (cART)
(6–8). Since the HLA class I-encoded gene products present virus-derived T-cell
epitopes to CD8 T cells, an extensive number of studies exist that have also linked
T-cell responses and their speciﬁcities to HIV control (2, 9, 10). Aside from host genetics
and immune factors, viral factors, such as viral replication capacity and cell tropism,
have been associated with HIV control, although cell tropism has not been consistently
documented (11, 12).
During the course of HIV infection, a proportion of nonprogressor individuals may
suffer a disruption of their capacity to control infection, which can manifest itself in
different ways, as follows: clinical progression deﬁned as a new AIDS-deﬁning event,
immunological progression deﬁned as an abrupt decrease of CD4 T-cell counts,
and/or virological progression as a signiﬁcant increase in viral loads (13–16). In addition,
HIV superinfection has been identiﬁed as a possible explanation for sudden signs of
uncontrolled HIV infection (17). Speciﬁc plasma cytokine proﬁles and Gag-speciﬁc T-cell
responses have been linked as well to eventual loss of control in an elite controller
cohort (18). However, the contribution of these factors to a sudden loss of control is
poorly deﬁned, in part due to the scarce availability of longitudinal samples from such
individuals, especially of samples close to the time point before loss of viral control
(LoC). Here, we have identiﬁed and longitudinally followed 14 individuals who experi-
enced an abrupt transition to progressive HIV infection with pre- and post-LoC samples
available within 1 year, and we have integrated host, virological, and immune param-
eters in order to better deﬁne the mechanisms underlying the progression of HIV-1
infection.
RESULTS
Clinical characteristics of HIV controllers experiencing abrupt LoC. For the
present analyses, 14 individuals with LoC were identiﬁed after reviewing clinical criteria
and sample availability for HIV-infected individuals with elite controller (EC) or viremic
controller (VC) status from the IrsiCaixa and the BioBank Controllers cohorts (Table 1).
The evolution of viral load and CD4 counts is shown in Fig. S1 in the supplemental
material. Samples prior to LoC were obtained with a median of 20 months before the
ﬁrst signs of LoC deﬁned either as detection of uncontrolled viral load (n  4) or a
concomitant raise in viral load and reduction in CD4 counts (n  10, Fig. S1). Follow-up
samples included samples taken at ﬁrst diagnosis of LoC (n  11) or within the
following 6 months (n  3). As HIV control has been linked to HLA class I genotypes,
high-resolution HLA class I typing was performed on all 14 individuals included in the
study. In line with data from other cohorts of elite and viremic controllers (19, 20),
protective HLA class I alleles B57 and B58 were more common in this group of
individuals (Fig. 1) than in the general population in Spain and similar to the frequen-
cies seen in the EC and VC comparison group established at our center. Thus, in this
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relatively small cohort, no speciﬁc class I HLA was associated with LoC in individuals
with previous HIV control.
Evidence for virus tropism change and superinfection between pre- and post-
LoC time points. In order to determine whether changes in the cellular tropism of
plasma virus preceded the abrupt loss of virus control, we determined viral tropism in
plasma samples drawn before (n  9; median, 21 months; range, 5 to 74 months) and
after (n  11), at diagnosis (n  8), or during the peak of viremia (n  3) clinical
progression. Of the 14 samples obtained while the individuals had controlled infection,
viral sequences covering the V3-loop (gp160) in all cases were indicative of a dominant
CCR5-tropic viral population. In contrast, CXCR4-tropic plasma viruses were detected in
four individuals post-LoC (although one of the individual was approaching the false-
positive threshold of 10%), of which three had conﬁrmed R5 virus pre-LoC (one did not
amplify for env; Table 2). Based on phylogenetic analyses of Gag sequences, all pre- and
post-LoC sequences showed close clustering for each individual except for one (subject
LP4, Fig. 2), suggesting a superinfection event. Overall, clear evidence for changes in
cell tropism were observed in one-quarter of the studied cohort, while superinfection
was not a generalized mechanism for LoC in this group of patients.
Virus maintained HLA-associated escape mutations. Viral breakthrough from
immune surveillance has been described for both T- and B-cell-mediated immune
control and could contribute to the sudden raise in viral loads and clinical HIV disease
progression (21, 22). In order to evaluate whether the presence and accumulation of
T-cell escape mutations contribute to LoC, HIV Gag sequences were obtained from
FIG 1 HLA class I allele frequencies. HLA-B allele frequencies are shown for the general Spanish
population (64), a cohort of elite controllers (EC, n  38), viremic controllers (VC, n  27), and individuals
that have abruptly lost their capacity to control the infection (LoC, n  14).
TABLE 2 HIV tropism before and after loss of control HIV tropism was estimated by
Gp120 V3-loop region sequencing before and after late progressiona
ID Control-Pre (%FPR) LoC-Post (%FPR)
LP1 NA CCR5 (12.5)
LP2 CCR5 (36.2) CXCR4 (0.1)
LP3 CCR5 (35.5) CCR5 (35.3)
LP4 NA CXCR4 (3.2)
LP5 CCR5 (13.2) CXCR4 (8.6)
LP6 NA NA
LP7 CCR5 (36.2) CXCR4 (4.8)
LP8 CCR5 (10) CCR5 (41.4)
LP9 CCR5 (55) CCR5 (28.8)
LP10 CCR5 (42.3) CCR5 (28.8)
LP11 CCR5 (38) CCR5 (37.4)
LP12 NA CCR5 (86.5)
LP13 NA CCR5 (42.2)
LP14 CCR5 (55.1) CCR5 (55.1)
aThe false-positive rate (FPR) was set to 10% to identify X4 tropism. NA, sample not ampliﬁed.
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samples drawn before and after LoC and analyzed for the presence of HLA class I
footprints (23) (Fig. 2). All individuals yielded sequences in post-LoC samples, while HIV
Gag sequences were successfully ampliﬁed in 9 out of 14 pre-LoC samples when
subjects presented with effective in vivo virus control and low or undetectable viral
loads. Gag sequences were compared with described HLA-associated escape mutations
speciﬁc to the individuals’ HLA class I genotype (23). In 67% of patients with pre- and
post-LoC sequences available, the number of patient-HLA speciﬁc footprints increased
from pre- to post-LoC sequences. Despite this trend, the median number of footprints
post-LoC (median, 3 footprints; range 1 to 8 footprints) did not differ signiﬁcantly from
the frequency of HLA footprints pre-LoC (median, 2 footprints; range, 1 to 5 footprints;
Fig. 3, P 0.2682). Although limited to Gag, the target of some of the most effective
FIG 2 Evolutionary relationships of taxa. The evolutionary history was inferred using the neighbor-joining method
(65). The optimal tree with the sum of branch length of 1.91362276 is shown. The percentage of replicate trees in
which the associated taxa clustered together in the bootstrap test (1,000 replicates) is shown next to the branches
(66). The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used
to infer the phylogenetic tree. The evolutionary distances were computed using the Tamura-Nei method (67) and
are in the units of the number of base substitutions per site. The rate variation among sites was modeled with a
gamma distribution (shape parameter  1). The analysis was based on a 66-nucleotide amplicon in the V3-loop of
HIV gp120. All ambiguous positions were removed for each sequence pair. Evolutionary analyses were conducted
in MEGA5 (68).
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antiviral T-cell responses (10), and although single epitope mutations can lead to a
complete loss of control, these data do not suggest that broad cytotoxic T lymphocyte
(CTL) escape on multiple epitopes is the major driving force for LoC in the present
cohort.
Increased number of HIV-speciﬁc T-cell responses post-LoC. Individuals that
control HIV infection have been shown to have a robust HIV-1-speciﬁc CD8 T-cell
response, especially against the Gag protein, compared to responses observed in
noncontrollers (10, 24). The HIV-speciﬁc CD8 T cells responses before LoC were thus
measured and compared to those of post-LoC samples and to responses seen in 65
individuals from the IrsiCaixa Controllers cohort. Responses to the entire HIV proteome
were measured by gamma interferon (IFN-) enzyme-linked immunosorbent spot assay
(ELISPOT) using a 410-overlapping-peptide set, covering the complete HIV genome, as
described previously (25). Twelve out of the 14 individuals had sufﬁcient cell viability to
conduct longitudinal full-proteome HIV ELISPOT screens (Fig. 3). In nine of them, the
number of individual responses remained stable (n  1 individual) or increased (n  8
individuals), with a signiﬁcant increase in the median breadth of response from 6
responses (range, 1 to 14 responses) pre-LoC to a median of 11 responses (range, 2 to
20 responses; Fig. 4A; P 0.0488). Even though the appearance of more responses
post-LoC may be due to higher viral replication and antigen availability post-LoC, the
increase in the breadth of responses did not result in a signiﬁcant increase in the total
magnitude (median magnitude from pre-LoC, 3,145 spot-forming cells [SFC]/million
peripheral blood mononuclear cells [PBMC; range, 100 to 7,950 SFC/million PBMC] to
median post-LoC of 4,745 SFC/million PBMC [range, 690 to 27,420 SFC/million PBMC;
FIG 3 Number of HLA escape mutations in Gag (23) detected in viral population from samples before and
after loss of control.
FIG 4 HIV-speciﬁc T-cell responses. (A) Breadth of HIV-speciﬁc T-cell responses before and after loss of control (n
12). (B) Magnitude of responses, expressed as SFC/million PBMC, is shown longitudinally (C) Gag dominance
(magnitude of Gag responses/total magnitude) is shown before and after evolution in the 12 LoC subjects and
compared to a cohort of elite (EC) and viremic (VC) controllers (n  65). Individuals that maintained an CCR5
tropism are shown in black dots, individuals that changed to a CXCR4 are shown in gray dots, and the individual
from which tropism was not available is shown in white dots. P values are shown for Wilcoxon signed rank test in
a comparison of paired data and for Mann-Whitney test to compare between groups.
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Fig. 4B; P 0.6221]. Of note, the dominance of Gag-speciﬁc responses which charac-
terizes naturally controlling individuals was not lost after LoC and was similar to levels
tested in the comparison cohort of elite and viremic controllers (Fig. 4C andS3).
Furthermore, there was no consistent pattern in the emergence of new and expansion/
reduction of preexisting responses from pre- to post-LoC; however, while some indi-
viduals showed a clear loss of immunodominant responses to certain HLA-restricted
epitopes in the absence of detectable mutations, other patients maintained a stable
response pattern (Fig. S3). Furthermore, there were no differences in the changes in
responses between individuals in whom the virus changed tropism and individuals that
maintained R5-tropic virus. Interestingly, the one individual (LP4) that showed evidence
of superinfection had a limited breadth of responses pre-LoC (4 responses), of which
only 2 were still detectable post-LoC, while there were an additional 15 responses
detected post-LoC, possibly reﬂecting new targets in the superinfecting virus. In this
individual, viral sequence data for Gag indicated that the pre-LoC virus contained all
described optimal epitopes for his HLA class I alleles in wild-type immunogenic
sequence, yet the subjects only mounted these Gag responses upon uncontrolled
superinfection (17).
Reduced antiviral capacity of CD8 T cells after loss of virological control. In
vitro inhibition of viral replication by autologous CD8 T cells has become a standard
measure to determine the ex vivo antiviral activity of cytotoxic T lymphocyte responses.
We asked whether the viral inhibition assay (VIA) activity in individuals suffering an
abrupt loss of control would be reduced at pre-LoC in comparison to persistent elite
and viremic controllers and how VIA activity would change after LoC. In the absence of
autologous virus isolates, the HIV IIIB laboratory strain was used to test in vitro
inhibitory capacity of PBMC-derived CD8 T cells. As a comparison, isolated CD8 T
cells from longitudinal PBMC samples of eight long-term HIV controllers with persistent
in vivo HIV control (n  6 EC and n  2 VC, 15 years of diagnosed HIV-2 infection;
longitudinal samples were 102 [range, 45 to 156] months apart between both follow-up
time points) were tested (Table S1). Viral replication was measured by ﬂow cytometry
as a percentage of HIV Gag p24-positive cells in culture. The results showed a strong
capacity of CD8 T cells from pre-LoC samples to inhibit HIV replication at a 1:1 E/T
(effector-to-target cells) ratio. However, this activity at the 1:1 ratio among the LoC
patients studied here was somewhat lower than that of HIV controllers (median, 65%
of LoC individuals compared to 84% of controllers, P 0.0650; Fig. 5A) and signiﬁcantly
weaker at the 1:10 E/T ratio (median, 23% of LoC compared to 50% of controllers,
FIG 5 Viral inhibition capacity. Levels of CD8 viral inhibitory capacity are shown for IIIB E/T 1:1 (A) and E/T 1:10
(B) in individuals who presented a loss of control (n 8) and long-term controllers (n 8). Comparison of antiviral
capacity is expressed as % inhibition  [(fraction of p24cells in CD4 T cells cultured alone)  (fraction of
p24cells in CD4 T cells cultured with CD8 T cells)]/(fraction of p24 in CD4 T cells cultured alone)  100.
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P  0.0104; Fig. 5B). While virus-suppressive activity in long-term controllers was
maintained over time (P  0.8438; median, 102 months between both time points
tested), the suppressive capacity in LoC further decreased, especially detectable at the
1:1 ratio (P 0.0156, Fig. 5A) upon loss of control. Thus, the data suggest that declining
VIA activity over pre-LoC time points may be a prognostic marker for an increased
risk of LoC.
Elevated frequencies of CD38 and PD-1 expression in CD8 T cells after LoC.
The expression of CD38 and HLA-DR on T cells has been shown to be lower in treated
HIV-infected individuals under cART and in HIV controllers than in individuals with
progressive HIV disease. We therefore asked whether individuals experiencing LoC had
elevated levels of activated cells right before the loss of control and how the increased
virus replication post-LoC may impact CD38 and HLA-DR expression. The expression of
surface activation markers on CD4 and CD8 T cells was assessed by ﬂow cytometry
before and after a loss of HIV control, along with additional activation markers (HLA-DR,
CD38, CD25, and CD69) and an exhaustion marker (PD-1). Longitudinal samples from
persistent HIV controllers were tested for comparison (102 months apart; range, 45 to
156 months). The expression of activation markers pre-LoC was similar to that in
long-term controllers (data not shown); therefore, there was no evidence for elevated
residual viral replication in LoC that could drive higher levels of activated T cells. In
contrast, an almost 2-fold increase in the percentage of CD38 and a trend toward
higher levels of HLA-DR CD8 cells were observed after a loss of control (P 0.0156 for
CD38, P 0.0781 for HLA-DR, and P 0.1563 for HLA-DR CD38). No alterations in
the expression of CD25 or CD69 were observed over time in either CD8 (Fig. 6A) or
CD4 T-cell populations among LoC individuals and did not differ in expression levels
observed in long-term controllers (data not shown). In line with previous reports (26),
CD8 T cells also expressed higher levels of PD-1 post-LoC (P 0.0156, Fig. 6A),
especially in central memory cells (CD8 CCR7-CD45RA), while those levels were
maintained in persistent controllers (Fig. 6B). Of note, there was a signiﬁcantly higher
level of PD-1 CD8 T cells with a naive phenotype (CCR7 CD45RA) in the individ-
uals with LoC than in persistent controllers. Importantly, this difference was already
manifest before LoC, potentially identifying an additional risk marker for subse-
quent LoC.
DISCUSSION
The search for reliable predictors of HIV control has been largely focused on
cross-sectional comparisons between individuals with either controlled or uncontrolled
HIV infection in the absence of antiretroviral treatment. These studies have yielded a
number of correlates of control, many pointing toward an important role of the
virus-speciﬁc cellular immunity in the natural control of HIV (27–30). Interpretation of
such studies, however, can be limited by its cross-sectional nature and, consequently,
by signiﬁcant potential differences in host genetics between comparison groups, in
particular, HLA class I allele frequencies (8, 31). In the present study, we have attempted
to overcome some of these limitations by analyzing longitudinal samples from subjects
who spontaneously lose their previously excellent and longstanding control of viral
replication. The identiﬁcation of markers of control, or loss thereof, could be a helpful
tool for the clinical management of individuals off cART with controlled HIV infection
and could have important implications for future prevention and treatment strategies
in general.
One possible explanation for the abrupt HIV disease progression observed in the
present cohort could be HIV superinfection. Superinfection with HIV has been associ-
ated with disease progression (17, 32) and has been previously documented, even in
the setting of HIV controller cohorts (33–35). Although superinfection can be facilitated
by exposure to a virus that can escape preexisting virus-speciﬁc T-cell immunity (33, 36),
the ﬁrst well-documented case of an uncontrolled superinfection in an HIV controller
occurred in the presence of a majority of T-cell epitopes being conserved between the
ﬁrst and second infecting virus (17). Interestingly, in the one case of suspected
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superinfection in the present cohort, we observed a complete change in the pattern of
CD8 T-cell responses, where only 2 responses were maintained (in Pol and Nef), while
15 new responses toward the whole proteome of HIV were mounted; however, they
were evidently not able to control the new virus. Although limited by the cohort size,
the present data are in line with earlier reports of highly immunogenic but uncontrolled
superinfection and suggest that superinfection may not be a major factor in the sudden
loss of virus control in former HIV controllers.
An alternative explanation for LoC could be a switch in the viral tropism from CCR5
to CXCR4, which has been described to precede a decrease in CD4 T-cell counts and
progression to AIDS (37–40). We found that 30% of the individuals (4 out of 13 tested)
presented X4-tropic virus after progression, while none was detected during the
controlled stages of infection. Interestingly, one of the individuals that showed an
X4-tropic virus was the subject that acquired superinfection, suggesting that the
second viral infection may have been with an X4-tropic virus. For the remaining 3
subjects who harbored X4 virus post-LoC, it remains unclear whether the change of
tropism was either the cause or the consequence of the loss of control. Actually, despite
signiﬁcant advances in the study of relevant parameters involved in HIV control, it is still
difﬁcult to deﬁne the causality dilemma of certain factors, such as the HIV tropism
evolution (28). Although a switch in coreceptor usage has been attributed to an
increase in viral ﬁtness (41, 42), we were unable to obtain any autologous virus from
samples drawn at time points when the individuals were controlling the infection and
thus could not compare viral replicative ﬁtness pre- and post-LoC. Cell tropism of HIV
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has also been associated with cell type-speciﬁc differences in antigen processing and,
hence, differences in epitope presentation on infected T cells versus infected macro-
phages or dendritic cells (43). An R5-to-X4 tropism change could therefore result in an
effective escape from T-cell immunity that is mainly focused on epitopes presented by
infected T cells but not by macrophages. In addition, it could also explain the marked
increase in responses post-LoC in the subject with superinfection and that env re-
sponses were only seen after superinfection, although the epitopes were present in
wild-type sequence in the controlled virus pre-LoC. As only three individuals showed
evidence of a dominant X4-tropic virus post-LoC, we were not able to identify any
speciﬁc response pattern that could correlate with tropism change during HIV infection
progression.
As referred to above, HIV controller cohorts are oftentimes enriched in particular
“beneﬁcial” HLA class I alleles, including HLA-B*27, HLA-B*57, and others (6). Our cohort
of LoC is no exception to this, as the frequency of those protective HLA class I alleles
(B57/58 and B27) was the same as observed in a locally recruited elite and viremic
controller cohort (44). Furthermore, we also detected broad and strong CTL responses,
especially toward Gag, consistent with previous reports in comparable cohorts (2,
45–48). However, it has also been suggested that HIV controllers with beneﬁcial or
nonbeneﬁcial HLA class I alleles may control HIV through different mechanisms, with
subjects expressing nonbeneﬁcial alleles, such as HLA-B*35, depending critically on
their T-cell responses to durable control (44). As our cohort only included one subject
with a strong nonbeneﬁcial HLA class I alleles, the study of larger cohorts of LoC with
unfavorable HLA class I genetics will offer a unique opportunity to determine whether
the failures of these responses are indeed critical determinants in LoC. In addition, more
in-depth characterization of these responses, including avidity testing and effector
function proﬁling (49, 50), rather than its mere presence/absence pre- and post-LoC,
may reveal factors that deﬁne the “failure” of these responses post-LoC. We addressed
the measurement of functional activity here by conducting in vitro inhibition assays
(VIA) on samples pre- and post-LoC. Our results indeed showed decreased antiviral in
vitro capacity of CD8 T cells before LoC compared to persistently controlling EC. Still,
the data suggest that declined VIA activity may precede a loss of control and could
serve as a predictor of failing immune control. This is in line with cross-sectional
analyses that have associated antiviral capacity of CD8 T-cell in VIA with the rate of HIV
disease progression and CD4 T-cell decline (13, 24). Thus, monitoring VIA activity in
untreated individuals may be a useful tool to initiate cART in a timely manner and may
be especially useful in treatment interruption studies that assess outcomes of thera-
peutic vaccination and other HIV cure approaches.
Another well-accepted explanation for loss of effective immune control of viral
replication in vivo is the occurrence of CTL escape mutations in the targeted epitope.
Although most tested individuals presented an increased number of HLA-associated
escape mutation in their Gag sequence between pre- and post-LoC samples, the
differences in HLA footprints over time were not signiﬁcant. As a single escaped CTL
epitope may allow for a loss of control, it would be important to test epitope variants
for their true ability to escape CTL recognition. However, we did not have sufﬁcient
samples at hand to map all responses and assess the effects of epitope mutations on
CTL recognition. In addition, extended deep sequencing covering the entire viral
genome and additional sampling time points close to LoC would provide more insights
into the role that HLA-associated mutations outside Gag may play in the abrupt the loss
of control. Deep sequencing would also reveal low-frequency mutations present that
were missed by our analyses and, with additional sampling points, allow the evolution
and frequencies of these mutations to be closely followed. As the frequency of
individuals experiencing a marked rapid LoC is already low, having closer sampling
intervals in larger cohorts will be truly challenging. Due to technical hurdles and sample
availability needed to reliably amplify gag sequences in individuals with low or unde-
tectable viremia, we cannot compare the occurrence and frequency of Gag HLA-
associated escape mutations seen in our subjects with those in individuals with
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persistent control. However, existing data show that even in individuals with low levels
of viral replication, Gag viral evolution can be detected (45, 51), suggesting that their
presence does not necessarily need to lead to LoC.
In line with the loss of antiviral capacity and an increased viral replication in vivo, we
observed a signiﬁcant increase in the expression of markers of T-cell activation and
exhaustion (in particular, CD38 and PD-1), both of which have been linked to HIV
disease progression (9, 46–48, 52–54). Of note, LoC individuals showed a signiﬁcantly
higher level of PD-1-expressing CD8 T cells even before loss of control compared to
individuals that maintained their viral control over time. This was especially marked for
CD8 T cells with a naive phenotype and may represent an early sign of LoC during
which terminally differentiated T cells may reacquire a naive phenotype (55). These cells
may not be able to cope with ongoing viral replication and immune activation pre-LoC,
ultimately leading to full-blown loss of control and elevated viral loads. At the same
time, the increased levels of exhaustion markers could also explain the reduced VIA
activity seen pre-LoC. Moreover, the enhanced activation and effector phenotype of
CD8 T cells could lead to less proliferative capacity of cells in vitro and result in
reduced VIA activity seen post-LoC. If validated in further cohorts, our analyses may
thus have identiﬁed reduced VIA activity and elevated levels of PD-1 expression as
predictive markers of loss of control in individuals showing natural control of HIV and
may help improve their clinical management. The data may also help guide immune-
based therapeutic intervention to achieve a functional HIV cure by deﬁning minimal VIA
activities and preferred T-cell phenotypes that may warrant treatment interruptions.
In light of reports showing a predictive value of reservoir size and the rebound
kinetics of virus after stopping treatment (56–58) or, in on our case, after LoC, it would
have been interesting to determine the size of the viral reservoir in the LoC individuals
tested here. However, cell availability did not allow for such analyses. Despite some of
these limitations, the present report suggests that individuals who presented an abrupt
loss of HIV control had an impaired capacity to inhibit in vitro viral replication, maybe
due to the increased exhaustion of their CD8 T cells before LoC. Measuring these
parameters may help identify untreated HIV controllers that are at risk of losing control
and may offer a useful tool for monitoring individuals during treatment interruption
phases included in therapeutic vaccine trials or other cure strategies.
Earlier studies addressing loss of control in previous HIV controllers have also been
hampered by the small size of the cohorts of such particular individuals or have
attempted to address this question in simian immunodeﬁciency virus (SIV)-infected
macaques (59, 60) while assessing only one or additional aspects of host immunity and
their role in persistent virus control (28, 52, 61, 62). Among these, NK function (54),
polyfunctionality (18), and the occurrence of new mutations in relatively conserved viral
genes have been proposed to precede the abrupt loss of control. As in our study, these
analyses are limited by the difﬁculty of discerning cause from effect of these events or
mechanisms, and further work, possibly in SIV models, may be required to validate the
importance of the individual factors identiﬁed in predicting LoC.
MATERIALS AND METHODS
Study participants and samples. Among two existing cohorts of HIV-1-infected elite and viremic
controllers (deﬁned by sustained undetectable or low-level viremia, respectively [plasma viral load {pVL},
50 copies/ml or 2,000 copies/ml] for more than 1 year in the absence of ART), we identiﬁed 14
subjects who experienced an abrupt transition from a nonprogressive to a progressive state of HIV
infection (Table 1). All individuals had stable viremia at 3 log copies/ml before LoC for a median time
of 14 years since HIV diagnosis (interquartile range [IQR], 4 to 19 years). The transition to LoC was deﬁned
as (i)1-log pVL increase and/or (ii) loss of30% CD4 T-cell counts or drop below 350 CD4 T cells/ml
within 1 year. Samples were obtained from the Spanish HIVHGM BioBank supported by the Spanish
Instituto de Salud Carlos III and from the existing long-term sample repository at IrsiCaixa, in Badalona,
Spain. All subjects were HLA-typed for HLA-A, HLA-B, and HLA-C loci at high resolution, as described
previously (31). Data from a full-protein ELISPOT CTL screen of a group of 65 individuals from the IrsiCaixa
Controllers Cohort with persistent HIV control for a median time of 14 years since HIV diagnosis (IQR, 5
to 21 years) were included for comparisons and included 38 EC (median viral load, 50 copies/ml; median
CD4 count, 815 cells/mm3) and 27 viremic controllers (median VL, 545 copies/ml; median CD4 count, 616
cells/mm3). A subset of eight HIV-1 controllers with longer clinical follow-up and with prospective
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biological samples available at separated time points was selected for the viral inhibition assay com-
parison as long-term controllers (Table S1). All patients provided informed consent before providing
samples. The study was approved by the institutional ethical review board of the Hospital Universitari
Germans Trias i Pujol (reference no. EO-09-041).
Gag sequence evolution. HIV-1 RNA was extracted from plasma using the QIAamp viral RNA kit
(Qiagen) and was reverse transcribed using reverse transcription-PCR (RT-PCR) SuperScript III enzyme mix
(Invitrogen). The gag gene region was then ampliﬁed by nested PCR. Sequencing was performed by the
Genomics Core Facility at Germans Trias i Pujol Research Institute. Gag nucleotide alignment was
performed with MUSCLE (http://www.ebi.ac.uk/Tools/msa/muscle/) to generate the corresponding
multiple-sequence alignments (MSA). Nucleotide evolution models that best explained sequence evo-
lution within each MSA were identiﬁed using the MEGA5 Find Best DNA/Protein Models (ML) function.
The model with the lower score according to Bayesian information criteria implemented in MEGA5 was
selected to construct phylogenetic trees. Gag sequences obtained were further analyzed to determine
the number of HLA class I-associated immune escape mutations and were identiﬁed based on the
individual’s HLA class I genotype and the HLA-associated escape mutations described by Brumme et al.
(23).
Determination of viral tropism. HIV tropism was predicted by Gp160 V3-loop region Sanger
sequencing, as previously described (63). Brieﬂy, HIV-1 RNA was extracted from plasma using the QIAamp
viral RNA kit (Qiagen), and cDNA was synthetized using RT-PCR SuperScript III enzyme mix (Invitrogen).
The env V3-loop-encoding region was ampliﬁed by nested PCR. Sequences were analyzed by using the
Geno2Pheno [coreceptor] using a false-positive rate (FPR) cutoff of 10% to deﬁne the presence of an X4
HIV-1.
IFN- ELISPOT. All individuals were screened longitudinally for IFN--secreting T-cell responses to
the entire HIV proteome. Brieﬂy, cryopreserved PBMC were thawed and rested for 5 h at 37°C before
plating 100,000 live cells per well in IFN- ELISPOT 96-well polyvinylidene plates (Millipore). PBMC were
stimulated with a clade B consensus sequence set of 410 peptides (18mers overlapping by 11 amino
acids [aa]) at a ﬁnal concentration of 14 g/ml. The IFN- Mabtech kit was used, according to the
manufacturer’s instructions. Spots were counted using an automated ELISPOT reader system (Immuno-
Spot S6 Versa; CTL, Germany), and the magnitude of responses was expressed as spot-forming cells (SFC)
per million input cells. The threshold for positive responses was deﬁned as at least 5 spots per well,
responses exceeding the “mean number of spots in negative-control wells plus 3 standard deviations of
the negative-control wells” and “three times the mean of negative-control wells,” whichever was higher.
Viral inhibition assay. The capacity of CD8 T cells to suppress HIV-1 replication in autologous CD4
T cells ex vivo was assessed as described in detail elsewhere (69, 70). Brieﬂy, CD8-depleted cells were
isolated from cryopreserved PBMC by magnetic bead separation (MACS Milteny Biotec) and stimulated
with phytohemagglutinin (PHA; 5 g/ml) for 3 days in R10-RPMI medium supplemented with 10% fetal
calf serum (FCS), L-glutamine (2 mM), penicillin (100 U/ml), and streptomycin (100 g/ml). Cells were then
washed and infected by spinoculation with an HIV-1 IIIB strain at a multiplicity of infection (MOI) of 0.01.
To assess the antiviral capacity of CD8 T cells, autologous infected CD4 T cells were cultured alone or
with unstimulated CD8 T cells in R10 supplemented with interleukin 2 (20 IU/ml). The experiments were
carried out in triplicate at different effector-to-target ratios (1:1, 1:10, and 1:2, depending on cell
availability). After 6 days of coculture, intracellular p24 production was measured by ﬂow cytometry.
Antiviral capacity was expressed as percentage of inhibition, determined as [(fraction of p24 cells in
CD4 T cells cultured alone)  (fraction of p24 in CD4 T cells cultured with CD8 cells)]/(fraction of
p24 cells in CD4 T cells cultured alone)  100.
Flow cytometry. CD8-depleted cells (CD4 T-cell enriched fraction) and CD8-isolated T cells were
stained for activation and exhaustion markers. Cells were ﬁrst stained with a viability staining (Aqua
LIVE/DEAD ﬁxable dead cell stain kit; Invitrogen), followed by exclusion staining of B lymphocytes and
myeloid cells using combined markers in a dump channel (using the cells/antibodies CD19/BV510 and
CD14/BV510; BioLegend). For T-cell lineage and activation markers, the following cells/antibodies were
used: CD3/antigen-presenting cells (APC) Cy7, CD4/peridinin chlorophyll protein (PerCP) (BD Biosci-
ences); and CD8/PerCP, CCR7/BV421, CD45RAPECF594/HLA-DR ﬂuorescein isothiocyanate (FITC), PD-1/
phycoerythyrin (PE,) CD69/APC, CD38/BV785, and CD25/BV605 (BioLegend). After staining, cells were
collected on an LSRFortessa instrument (BD), and analysis was performed using the FlowJo 10 software.
To determine the number of p24 cells in the viral inhibition assay, cells were stained with Aqua
LIVE/DEAD (Invitrogen), followed by extracellular staining with cells/antibodies CD3/APC-H7, CD4/PerCP,
and CD8/APC (BD Biosciences). Cells were ﬁxed and permeabilized (FIX & PERM cell ﬁxation & cell
permeabilization kit; Thermo Fisher Scientiﬁc) and ﬁnally stained with p24 antibody KC.57 ﬂuorescein
isothiocyanate (FITC; Beckman Coulter). Samples were acquired on an LSR-II cytometer, and data analysis
was done using the FlowJo 10 software.
Statistical analysis. GraphPad Prism version 7.0 for Windows (San Diego, CA) was used to compare
response rates in both groups and subgroup analyses. A Mann-Whitney test and Wilcoxon matched
paired test were used for unpaired and paired comparisons, respectively.
Data availability. Gag sequences are available at GenBank with the accession numbers MK086511
(LP1), MK086512 (LP2 pre), MK086513 (LP2 post), MK086514 (LP3 pre), MK086515 (LP3 post), MK086516
(LP4 pre), MK086517 (LP4 post), MK086518 (LP5 pre), MK086519 (LP5 post), MK086520 (LP6 post),
MK086521 (LP7 post), MK086522 (LP8 pre), MK086523 (LP8 post), MK086524 (LP9 pre), MK086525 (LP9
post), MK086526 (LP10 post), MK086527 (LP11 pre), MK086528 (LP11 post), MK086529 (LP12 pre),
MK086530 (LP12 post), MK086531 (LP13 post), MK086532 (LP14 pre), and MK086533 (LP14 post).
Rosás-Umbert et al. Journal of Virology
February 2019 Volume 93 Issue 4 e01436-18 jvi.asm.org 12
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/JVI
.01436-18.
SUPPLEMENTAL FILE 1, PDF ﬁle, 0.9 MB.
ACKNOWLEDGMENTS
We particularly thank the patients in this study for their participation and the HIV
BioBank, an integrated part of the Spanish AIDS Research Network, and collaborating
centers for the generous provision of clinical samples.
The HIV BioBank is supported by Instituto de Salud Carlos III and Spanish Health
Ministry (grant RD06/0006/0035). This work was supported in part by the Spanish FIPSE
gant 360737-09, the Barcelona-based HIVACAT program, funding from the European
Union’s Horizon 2020 research and innovation program under grant agreement
681137-EAVI2020, and a research agreement with AELIX Therapeutics, Barcelona, Spain.
Christian Brander is the CSO at AELIX Therapeutics.
REFERENCES
1. Buchbinder SP, Katz MH, Hessol NA, O’Malley PM, Holmberg SD. 1994.
Long-term HIV-1 infection without immunologic progression. AIDS
8:1123–1128. https://doi.org/10.1097/00002030-199408000-00014.
2. Deeks SG, Walker BD, Cellerai C, Vallelian F, Bart PA, Pantaleo G, Lifson
JD, O’Connor DH, Carrington M, Watkins DI. 2007. Human immunodeﬁ-
ciency virus controllers: mechanisms of durable virus control in the
absence of antiretroviral therapy. Immunity 27:406–416. https://doi.org/
10.1016/j.immuni.2007.08.010.
3. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B,
Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T,
Petropoulos CJ, Rosenberg ES, Walker BD. 2008. Genetic and immuno-
logic heterogeneity among persons who control HIV infection in the
absence of therapy. J Infect Dis 197:563–571. https://doi.org/10.1086/
526786.
4. Sáez-Cirión A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C,
Boufassa F, Avettand-Fènoël V, Rouzioux C, Delfraissy J-F, Barré-Sinoussi
F, Lambotte O, Venet A, Pancino G, ANRS EP36 HIV Controllers Study
Group. 2009. Heterogeneity in HIV suppression by CD8 T cells from HIV
controllers: association with Gag-speciﬁc CD8 T cell responses. J Immu-
nol 182:7828–7837. https://doi.org/10.4049/jimmunol.0803928.
5. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang
K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easter-
brook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith
JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL, McMichael AJ,
Haynes BF, Telenti A, Goldstein DB. 2007. A whole-genome association
study of major determinants for host control of HIV-1. Science 317:
944–947. https://doi.org/10.1126/science.1143767.
6. Carrington M, O’Brien SJ. 2003. The inﬂuence of HLA genotype on AIDS.
Annu Rev Med 54:535–551. https://doi.org/10.1146/annurev.med.54
.101601.152346.
7. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, Urban
TJ, Zhang K, Gumbs CE, Smith JP, Castagna A, Cozzi-Lepri A, De Luca A,
Easterbrook P, Günthard HF, Mallal S, Mussini C, Dalmau J, Martinez-
Picado J, Miro JM, Obel N, Wolinsky SM, Martinson JJ, Detels R, Margolick
JB, Jacobson LP, Descombes P, Antonarakis SE, Beckmann JS, O’Brien SJ,
Letvin NL, McMichael AJ, Haynes BF, Carrington M, Feng S, Telenti A,
Goldstein DB, NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI).
2009. Common genetic variation and the control of HIV-1 in humans.
PLoS Genet 5:e1000791. https://doi.org/10.1371/journal.pgen.1000791.
8. Goulder PJR, Walker BD. 2012. HIV and HLA class I: an evolving relation-
ship. Immunity 37:426–440. https://doi.org/10.1016/j.immuni.2012.09
.005.
9. Sáez-Cirión A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa
F, Barré-Sinoussi F, Delfraissy J-F, Sinet M, Pancino G, Venet A, Agence
Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group.
2007. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV
infection ex vivo and peculiar cytotoxic T lymphocyte activation pheno-
type. Proc Natl Acad Sci U S A 104:6776–6781. https://doi.org/10.1073/
pnas.0611244104.
10. Zuñiga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, Hernandez A,
Sanchez H, Frahm N, Linde CH, Hewitt HS, Hildebrand W, Altfeld M, Allen
TM, Walker BD, Korber BT, Leitner T, Sanchez J, Brander C. 2006. Relative
dominance of Gag p24-speciﬁc cytotoxic T lymphocytes is associated
with human immunodeﬁciency virus control. J Virol 80:3122–3125.
https://doi.org/10.1128/JVI.80.6.3122-3125.2006.
11. Payne R, Muenchhoff M, Mann J, Roberts HE, Matthews P, Adland E,
Hempenstall A, Huang K-H, Brockman M, Brumme Z, Sinclair M, Miura T,
Frater J, Essex M, Shapiro R, Walker BD, Ndung’u T, McLean AR, Carlson
JM, Goulder PJR. 2014. Impact of HLA-driven HIV adaptation on virulence
in populations of high HIV seroprevalence. Proc Natl Acad Sci 111:
E5393–E5400. https://doi.org/10.1073/pnas.1413339111.
12. Casadellà M, Cozzi-Lepri A, Phillips A, Noguera-Julian M, Bickel M, Sed-
lacek D, Zilmer K, Clotet B, Lundgren JD, Paredes R, EuroSIDA in Euro-
COORD. 2017. Plasma HIV-1 tropism and the risk of short-term clinical
progression to AIDS or death. PLoS One 12:e0166613. https://doi.org/
10.1371/journal.pone.0166613.
13. Okulicz JF, Marconi VC, Landrum ML, Wegner S, Weintrob A, Ganesan A,
Hale B, Crum-Cianﬂone N, Delmar J, Barthel V, Quinnan G, Agan BK,
Dolan MJ, Infectious Disease Clinical Research Program (IDCRP) HIV
Working Group. 2009. Clinical outcomes of elite controllers, viremic
controllers, and long-term nonprogressors in the US Department of
Defense HIV natural history study. J Infect Dis 200:1714–1723. https://
doi.org/10.1086/646609.
14. Van der Helm JJ, Geskus R, Lodi S, Meyer L, Schuitemaker H, Gunsenheimer-
Bartmeyer B, Monforte A. dArminio, Olson A, Touloumi G, Sabin C, Porter
K, Prins M, CASCADE Collaboration in EuroCoord. 2014. Characterisation
of long-term non-progression of HIV-1 infection after seroconversion:
a cohort study. Lancet HIV 1:e41–e48. https://doi.org/10.1016/S2352
-3018(14)70016-5.
15. Noel N, Lerolle N, Lécuroux C, Goujard C, Venet A, Saez-Cirion A,
Avettand-Fenoël V, Meyer L, Boufassa F, Lambotte O, Agut H, Autran B,
Barin F, Costagliola D, Pancino G, Rouzioux C, Samri-Hassimi A, Taulera
O, Theodorou I, Tubiana R, Viard JP, Yazdanpanah Y, Boufassa F, Lam-
botte O, Meyer L. 2015. Immunologic and virologic progression in HIV
controllers: the role of viral “blips” and immune activation in the ANRS
CO21 CODEX study. PLoS One 10:1–11.
16. Leon A, Perez I, Ruiz-Mateos E, Benito JM, Leal M, Lopez-Galindez C,
Rallon N, Alcami J, Lopez-Aldeguer J, Viciana P, Rodriguez C, Grau E,
Iribarren J, Gatell JM, Garcia F, EC and Immune Pathogenesis Working
group of the Spanish AIDS Research Network. 2016. Rate and predictors
of progression in elite and viremic HIV-1 controllers. AIDS 30:1209–1220.
https://doi.org/10.1097/QAD.0000000000001050.
17. Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, Mon-
teﬁori DC, O’Connor DH, Davis BT, Lee PK, Maier EL, Harlow J, Goulder
PJR, Brander C, Rosenberg ES, Walker BD. 2002. HIV-1 superinfection
despite broad CD8 T-cell responses containing replication of the pri-
mary virus. Nature 420:434–439. https://doi.org/10.1038/nature01200.
18. Pernas M, Tarancón-Diez L, Rodríguez-Gallego E, Gómez J, Prado JG,
Casado C, Dominguez-Molina B, Olivares I, Coiras M, León A, Rodriguez
C, Benito JM, Rallón N, Plana M, Martinez-Madrid O, Dapena M, Iribarren
Mechanisms of Spontaneous Loss of HIV Control Journal of Virology
February 2019 Volume 93 Issue 4 e01436-18 jvi.asm.org 13
JA, del Romero J, García F, Alcamí J, Muñoz-Fernández MÁ, Vidal F, Leal
M, Lopez-Galindez C, Ruiz-Mateos E, on behalf of ECRIS integrated in the
Spanish AIDS Research Network. 2018. Factors leading to the loss of
natural elite control of HIV-1 infection. J Virol 92:e01805-17. https://doi
.org/10.1128/JVI.01805-17.
19. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM,
Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M.
2000. HLA B*5701 is highly associated with restriction of virus replication
in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad
Sci U S A 97:2709–2714. https://doi.org/10.1073/pnas.050567397.
20. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, McCune JM,
Deeks SG. 2008. HLA class I-restricted T-cell responses may contribute to
the control of human immunodeﬁciency virus infection, but such re-
sponses are not always necessary for long-term virus control. J Virol
82:5398–5407. https://doi.org/10.1128/JVI.02176-07.
21. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A,
Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H,
Aceto L, Günthard HF. 2005. Delay of HIV-1 rebound after cessation of
antiretroviral therapy through passive transfer of human neutralizing
antibodies. Nat Med 11:615–622. https://doi.org/10.1038/nm1244.
22. Goulder PJR, Walker BD. 1999. The great escape – AIDS viruses and
immune control. Nat Med 5:1233–1235. https://doi.org/10.1038/15184.
23. Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman MA,
Swenson LC, Tao I, Szeto S, Rosato P, Sela J, Kadie CM, Frahm N, Brander
C, Haas DW, Riddler SA, Haubrich R, Walker BD, Harrigan PR, Heckerman
D, Mallal S. 2009. HLA-associated immune escape pathways in HIV-1
subtype B Gag, Pol and Nef proteins. PLoS One 4:e6687. https://doi.org/
10.1371/journal.pone.0006687.
24. Berger CT, Frahm N, Price DA, Mothe B, Ghebremichael M, Hartman KL,
Henry LM, Brenchley JM, Ruff LE, Venturi V, Pereyra F, Sidney J, Sette A,
Douek DC, Walker BD, Kaufmann DE, Brander C. 2011. High-functional-
avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-
derived epitopes associated with relative HIV control. J Virol 85:
9334–9345. https://doi.org/10.1128/JVI.00460-11.
25. Frahm N, Korber BT, Adams CM, Szinger JJ, Draenert R, Addo MM,
Feeney ME, Yusim K, Sango K, Brown NV, SenGupta D, Piechocka-Trocha
A, Simonis T, Marincola FM, Wurcel AG, Stone DR, Russell CJ, Adolf P,
Cohen D, Roach T, StJohn A, Khatri A, Davis K, Mullins J, Goulder PJR,
Walker BD, Brander C. 2004. Consistent cytotoxic-T-lymphocyte target-
ing of immunodominant regions in human immunodeﬁciency virus
across multiple ethnicities. J Virol 78:2187–2200. https://doi.org/10
.1128/JVI.78.5.2187-2200.2004.
26. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S,
Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J,
Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJR,
Klenerman P, Ahmed R, Freeman GJ, Walker BD. 2006. PD-1 expression
on HIV-speciﬁc T cells is associated with T-cell exhaustion and disease
progression. Nature 443:350–354. https://doi.org/10.1038/nature05115.
27. Mothe B, Ibarrondo J, Llano A, Brander C. 2009. Virological, immune
and host genetics markers in the control of HIV infection. Dis Markers
27:106–120.
28. Prado JG, Carrillo J, Blanco-Heredia J, Brander C. 2011. Immune corre-
lates of HIV control. Curr Med Chem 18:3963–3970. https://doi.org/10
.2174/092986711796957202.
29. Walker-Sperling VEK, Buckheit RW, Blankson JN. 2014. Comparative anal-
ysis of the capacity of elite suppressor CD4 and CD8 T cells to inhibit
HIV-1 replication in monocyte-derived macrophages. J Virol 88:
9789–9798. https://doi.org/10.1128/JVI.00860-14.
30. Migueles SA, Mendoza D, Zimmerman MG, Martins KM, Toulmin SA,
Kelly EP, Peterson BA, Johnson SA, Galson E, Poropatich KO, Patama-
wenu A, Imamichi H, Ober A, Rehm CA, Jones S, Hallahan CW, Follmann
DA, Connors M. 2015. CD8 T-cell cytotoxic capacity associated with
human immunodeﬁciency virus-1 control can be mediated through
various epitopes and human leukocyte antigen types. EBioMedicine
2:46–58. https://doi.org/10.1016/j.ebiom.2014.12.009.
31. Olvera A, Ganoza C, Pérez-Álvarez S, Hildebrand W, Sanchez J,
Brander C. 2014. HLA-B*35-PX and HLA-B*35-PY subtype differentia-
tion does not predict observed differences in level of HIV control in
a Peruvian MSM cohort. AIDS 28:2323–2325. https://doi.org/10.1097/
QAD.0000000000000403.
32. Smith DM, Wong JK, Hightower GK, Ignacio CC, Koelsch KK, Daar ES,
Richman DD, Little SJ. 2004. Incidence of HIV superinfection following
primary infection. JAMA 292:1177–1178. https://doi.org/10.1001/jama
.292.10.1177.
33. Clerc O, Colombo S, Yerly S, Telenti A, Cavassini M. 2010. HIV-1 elite
controllers: beware of super-infections. J Clin Virol 47:376–378. https://
doi.org/10.1016/j.jcv.2010.01.013.
34. Rachinger A, Navis M, van Assen S, Groeneveld PHP, Schuitemaker H.
2008. Recovery of viremic control after superinfection with pathogenic
HIV type 1 in a longterm elite controller of HIV type 1 infection. Clin
Infect Dis 47:e86–e89. https://doi.org/10.1086/592978.
35. Brener J, Gall A, Hurst J, Batorsky R, Lavandier N, Chen F, Edwards A,
Bolton C, Dsouza R, Allen T, Pybus OG, Kellam P, Matthews PC, Goulder
PJR. 2018. Rapid HIV disease progression following superinfection in an
HLA-B*27:05/B*57:01-positive transmission recipient. Retrovirology 15:7.
https://doi.org/10.1186/s12977-018-0390-9.
36. Streeck H, Li B, Poon AFY, Schneidewind A, Gladden AD, Power KA,
Daskalakis D, Bazner S, Zuniga R, Brander C, Rosenberg ES, Frost SDW,
Altfeld M, Allen TM. 2008. Immune-driven recombination and loss of
control after HIV superinfection. J Exp Med 205:1789–1796. https://doi
.org/10.1084/jem.20080281.
37. Kaleebu P, Nankya IL, Yirrell DL, Shafer LA, Kyosiimire-Lugemwa J, Lule
DB, Morgan D, Beddows S, Weber J, Whitworth JAG. 2007. Relation
between chemokine receptor use, disease stage, and HIV-1 subtypes A
and D. J Acquir Immune Deﬁc Syndr 45:28–33. https://doi.org/10.1097/
QAI.0b013e3180385aa0.
38. Solomon A, Lane N, Wightman F, Gorry PR, Lewin SR. 2005. Enhanced
replicative capacity and pathogenicity of HIV-1 isolated from individuals
infected with drug-resistant virus and declining CD4 T-cell counts. J
Acquir Immune Deﬁc Syndr 40:140–148. https://doi.org/10.1097/01.qai
.0000173460.75322.93.
39. Connor RI, Mohri H, Cao Y, Ho DD. 1993. Increased viral burden and
cytopathicity correlate temporally with CD4 T-lymphocyte decline and
clinical progression in human immunodeﬁciency virus type 1-infected
individuals. J Virol 67:1772–1777.
40. Swanstrom R, Cofﬁn J. 2012. HIV-1 pathogenesis: the virus. Cold Spring
Harb Perspect Med 2:a007443. https://doi.org/10.1101/cshperspect
.a007443.
41. Troyer RM, Collins KR, Abraha A, Fraundorf E, Moore DM, Krizan RW,
Toossi Z, Colebunders RL, Jensen MA, Mullins JI, Vanham G, Arts EJ. 2005.
Changes in human immunodeﬁciency virus type 1 ﬁtness and genetic
diversity during disease progression. J Virol 79:9006–9018. https://doi
.org/10.1128/JVI.79.14.9006-9018.2005.
42. Weber J, Gibson RM, Sácká L, Strunin D, Hodek J, Weberová J, Pávová M,
Alouani DJ, Asaad R, Rodriguez B, Lederman MM, Quiñones-Mateu ME.
2017. Impaired human immunodeﬁciency virus type 1 replicative ﬁtness
in atypical viremic non-progressor individuals. AIDS Res Ther 14:15.
https://doi.org/10.1186/s12981-017-0144-0.
43. Dinter J, Duong E, Lai NY, Berberich MJ, Kourjian G, Bracho-Sanchez E,
Chu D, Su H, Zhang SC, Le Gall S. 2015. Variable processing and
cross-presentation of HIV by dendritic cells and macrophages shapes
CTL immunodominance and immune escape. PLoS Pathog 11:e1004725.
https://doi.org/10.1371/journal.ppat.1004725.
44. Koofhethile CK, Ndhlovu ZM, Thobakgale-Tshabalala C, Prado JG, Ismail
N, Mncube Z, Mkhize L, van der Stok M, Yende N, Walker BD, Goulder
PJR, Ndung’u T. 2016. CD8 T cell breadth and ex vivo virus inhibition
capacity distinguish between viremic controllers with and without pro-
tective. J Virol 90:6818–6831. https://doi.org/10.1128/JVI.00276-16.
45. Salgado M, Garcia-Minambres A, Dalmau J, Jiménez-Moyano E, Viciana P,
Alejos B, Clotet B, Prado JG, Martinez-Picado J. 2018. Control of HIV-1
pathogenesis in viremic nonprogressors is independent of Gag-speciﬁc
cytotoxic T lymphocyte responses. J Virol 92:e00346-18. https://doi.org/
10.1128/JVI.00346-18.
46. Choudhary SK, Vrisekoop N, Jansen CA, Otto SA, Schuitemaker H, Mie-
dema F, Camerini D. 2007. Low immune activation despite high levels of
pathogenic human immunodeﬁciency virus type 1 results in long-term
asymptomatic disease. J Virol 81:8838–8842. https://doi.org/10.1128/JVI
.02663-06.
47. Deeks SG, Kitchen CMR, Liu L, Guo H, Gascon R, Narváez AB, Hunt P,
Martin JN, Kahn JO, Levy J, McGrath MS, Hecht FM. 2004. Immune
activation set point during early HIV infection predicts subsequent CD4
T-cell changes independent of viral load. Blood 104:942–947. https://doi
.org/10.1182/blood-2003-09-3333.
48. Bansal A, Sterrett S, Erdmann N, Westfall AO, Dionne-Odom J, Overton
ET, Goepfert PA. 2015. Normal T-cell activation in elite controllers with
preserved CD4 T-cell counts. AIDS 29:2245–2254. https://doi.org/10
.1097/QAD.0000000000000860.
49. Mothe B, Llano A, Ibarrondo J, Zamarreño J, Schiaulini M, Miranda C,
Rosás-Umbert et al. Journal of Virology
February 2019 Volume 93 Issue 4 e01436-18 jvi.asm.org 14
Ruiz-Riol M, Berger CT, Herrero MJ, Palou E, Plana M, Rolland M, Khatri A,
Heckerman D, Pereyra F, Walker BD, Weiner D, Paredes R, Clotet B, Felber
BK, Pavlakis GN, Mullins JI, Brander C. 2012. CTL responses of high
functional avidity and broad variant cross-reactivity are associated with
HIV control. PLoS One 7:e29717. https://doi.org/10.1371/journal.pone
.0029717.
50. Betts MR, Price DA, Brenchley JM, Lore K, Guenaga FJ, Smed-Sorensen a,
Ambrozak DR, Migueles SA, Connors M, Roederer M, Douek DC, Koup
RA. 2004. The functional proﬁle of primary human antiviral CD8 T cell
effector activity is dictated by cognate peptide concentration. J Immu-
nol 172:6407–6417. https://doi.org/10.4049/jimmunol.172.10.6407.
51. Mens H, Kearney M, Wiegand A, Shao W, Schønning K, Gerstoft J, Obel
N, Maldarelli F, Mellors JW, Benﬁeld T, Cofﬁn JM. 2010. HIV-1 continues
to replicate and evolve in patients with natural control of HIV infection.
J Virol 84:12971–12981. https://doi.org/10.1128/JVI.00387-10.
52. Benito JM, Ortiz MC, León A, Sarabia LA, Ligos JM, Montoya M, Garcia M,
Ruiz-Mateos E, Palacios R, Cabello A, Restrepo C, Rodriguez C, Del
Romero J, Leal M, Muñoz-Fernández MA, Alcamí J, García F, Górgolas M,
Rallón N, ECRIS integrated in the Spanish AIDS Research Network. 2018.
Class-modeling analysis reveals T-cell homeostasis disturbances in-
volved in loss of immune control in elite controllers. BMC Med 16:30.
https://doi.org/10.1186/s12916-018-1026-6.
53. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page Shafer K,
Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG. 2008.
Relationship between T cell activation and CD4 T cell count in HIVse-
ropositive individuals with undetectable plasma HIV RNA levels in the
absence of therapy. J Infect Dis 197:126–133. https://doi.org/10.1086/
524143.
54. Walker-Sperling VE, Pohlmeyer CW, Veenhuis RT, May M, Luna KA,
Kirkpatrick AR, Laeyendecker O, Cox AL, Carrington M, Bailey JR, Arduino
RC, Blankson JN. 2017. Factors associated with the control of viral
replication and virologic breakthrough in a recently infected HIV-1
controller. EBioMedicine 16:141–149. https://doi.org/10.1016/j.ebiom
.2017.01.034.
55. Pulko V, Davies JS, Martinez C, Lanteri MC, Busch MP, Diamond MS, Knox
K, Bush EC, Sims PA, Sinari S, Billheimer D, Haddad EK, Murray KO,
Wertheimer AM, Nikolich-Žugich J. 2016. Human memory T cells with a
naive phenotype accumulate with aging and respond to persistent
viruses. Nat Immunol 17:966–975. https://doi.org/10.1038/ni.3483.
56. Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR,
Lederman MM, Para M, Gandhi RT. 2015. The size of the expressed HIV
reservoir predicts timing of viral rebound after treatment interruption.
AIDS 30:1.
57. Namazi G, Fajnzylber JM, Aga E, Bosch R, Acosta EP, Sharaf R, Hartogen-
sis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller
MC, Little SJ, Gianella S, Smith D, Kuritzkes DR, Gulick RM, Mellors JW,
Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks
S, Chun T-W, Collier AC, Routy J-P, Hecht FM, Walker BD, Li JZ. 2018. The
Control of HIV after Antiretroviral Medication Pause (CHAMP) study:
post-treatment controllers identiﬁed from 14 clinical studies. J Infect Dis
218:1954–1963. https://doi.org/10.1093/infdis/jiy479.
58. Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, Brumme ZL,
Aga E, Bosch RJ, Wen Y, Namazi G, Gao C, Acosta EP, Gandhi RT,
Jacobson JM, Skiest D, Margolis DM, Mitsuyasu R, Volberding P, Connick
E, Kuritzkes DR, Lederman MM, Yu XG, Lichterfeld M, Li JZ. 2018. HIV-1
proviral landscapes distinguish posttreatment controllers from noncon-
trollers. J Clin Invest 128:4074–4085. https://doi.org/10.1172/JCI120549.
59. Shytaj IL, Nickel G, Arts E, Farrell N, Biffoni M, Pal R, Chung HK, LaBranche
C, Monteﬁori D, Vargas-Inchaustegui D, Robert-Guroff M, Lewis MG,
Sacha JB, Palamara AT, Savarino A. 2015. Two-year follow-up of ma-
caques developing intermittent control of the human immunodeﬁ-
ciency virus homolog simian immunodeﬁciency virus SIVmac251 in the
chronic phase of infection. J Virol 89:7521–7535. https://doi.org/10.1128/
JVI.00396-15.
60. Burwitz BJ, Giraldo-Vela JP, Reed J, Newman LP, Bean AT, Nimityongskul
FA, Castrovinci PA, Maness NJ, Leon EJ, Rudersdorf R, Sacha JB. 2012.
CD8 and CD4 cytotoxic T cell escape mutations precede break-
through SIVmac239 viremia in an elite controller. Retrovirology 9:91.
https://doi.org/10.1186/1742-4690-9-91.
61. Thèze J, Chakrabarti LA, Vingert B, Porichis F, Kaufmann DE. 2011. HIV
controllers: a multifactorial phenotype of spontaneous viral suppression.
Clin Immunol 141:15–30. https://doi.org/10.1016/j.clim.2011.07.007.
62. Elahi S, Dinges WL, Lejarcegui N, Laing KJ, Collier AC, Koelle DM, McEl-
rath MJ, Horton H. 2011. Protective HIV-speciﬁc CD8 T cells evade Treg
cell suppression. Nat Med 17:989–995. https://doi.org/10.1038/nm.2422.
63. Bonjoch A, Pou C, Perez-Alvarez N, Bellido R, Casadella M, Puig J,
Noguera-Julian M, Clotet B, Negredo E, Paredes R. 2013. Switching the
third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a
pilot, prospective, randomized clinical trial. J Antimicrob Chemother
68:1382–1387. https://doi.org/10.1093/jac/dks539.
64. González-Galarza FF, Takeshita LYC, Santos EJM, Kempson F, Maia MHT,
da Silva ALS, Silva ALT. e, Ghattaoraya GS, Alﬁrevic A, Jones AR, Middle-
ton D. 2015. Allele frequency net 2015 update: new features for HLA
epitopes, KIR and disease and HLA adverse drug reaction associa-
tions. Nucleic Acids Res 43:D784–D788. https://doi.org/10.1093/nar/
gku1166.
65. Saitou N, Nei M. 1987. The neighbor-joining method: a new method for
reconstructing phylogenetic trees. Mol Biol Evol 4:406–425. https://doi
.org/10.1093/oxfordjournals.molbev.a040454.
66. Felsenstein J. 1985. Conﬁdence limits on phylogenies: an approach
using the bootstrap. Evolution 39:783–791. https://doi.org/10.1111/j
.1558-5646.1985.tb00420.x.
67. Tamura K, Nei M. 1993. Estimation of the number of nucleotide substitu-
tions in the control region of mitochondrial DNA in humans and chimpan-
zees. Mol Biol Evol 10:512–526. https://doi.org/10.1093/oxfordjournals
.molbev.a040023.
68. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011.
MEGA5: Molecular Evolutionary Genetics Analysis using maximum like-
lihood, evolutionary distance, and maximum parsimony methods. Mol
Biol Evol 28:2731–2739. https://doi.org/10.1093/molbev/msr121.
69. Yang H, Wu H, Hancock G, Clutton G, Sande N, Xu X, Yan H, Huang X,
Angus B, Kuldanek K, Fidler S, Denny TN, Birks J, McMichael AJ, Dorrell
L. 2012. Antiviral inhibitory capacity of CD8 T cells predicts the rate of
CD4 T-cell decline in HIV-1 infection. J Infect Dis 206:552–561. https://
doi.org/10.1093/infdis/jis379.
70. Yang H, Yorke E, Hancock G, Clutton G, Sande N, Angus B, Smyth R, Mak
J, Dorrell L. 2013. Improved quantiﬁcation of HIV-1-infected CD4  T cells
using an optimised method of intracellular HIV-1 gag p24 antigen
detection. J Immunol Methods 391:174–178. https://doi.org/10.1016/j
.jim.2013.03.001.
Mechanisms of Spontaneous Loss of HIV Control Journal of Virology
February 2019 Volume 93 Issue 4 e01436-18 jvi.asm.org 15
